Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin

Journal of Clinical Oncology

Volumn 19, Issue 12, 2001, Pages 3130-3141

  Peck, R A ^a   Hewett, J ^a   Harding, M W ^a   Wang, Y M ^a   Chaturvedi, P R ^a   Bhatnagar, A ^a   Ziessman, H ^a   Atkins, F ^a   Hawkins, M J ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIRICODAR; DOXORUBICIN; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; IN VITRO STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0035876039     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.12.3130     Document Type: Article

References (60)

1. Multidrug resistance in the laboratory and clinic
2. P-glycoprotein, multidrug resistance and tumor progression
3. Multidrug resistance: Molecular mechanisms and clinical relevance
4. Multidrug resistance in cancer chemotherapy
5. P-glycoprotein in adult solid tumors: Expression and prognostic significance
6. MDR1 gene expression in solid tumours
7. P-glycoprotein in adult hematologic malignancies
8. Clinical relevance of P-glycoprotein expression in haematological malignancies
9. Biology of the multidrug resistance-associated protein MRP
10. The function of the multidrug resistance proteins (MRP and cMRP) in drug conjugate transport and hepatobiliary excretion
11. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein
12. Tissue distribution of the multidrug resistance protein
13. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers
14. Expression pattern of MRP in human tissues and adult solid tumor cell lines
15. Expression of the gene for multi-drug resistance-associated protein and outcome in patients with neuroblastoma
16. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
17. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers
18. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
19. Therapeutic approach to drug resistant tumors
20. Clinical trials of P-glycoprotein reversal in solid tumours
21. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
22. Clinical trials of agents that reverse multidrug resistance: A literature review
23. Clinical studies with modulators of multidrug resistance
24. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance
25. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer
26. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (valspodar), in refractory malignancies
27. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of cancer and leukemia group B study 9420
28. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer
29. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer
30. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex
31. Tc-99m-sestamibi may be a transport substrate of the human multidrug resistance-associated protein (MRP)
32. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein
33. Modulation of the multidrug resistance P-glycoprotein: Detection with technetium-99m-sestabmibi in vivo
34. Clinical imaging of multidrug resistance in cancer
35. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: Correlation with mdr gene expression
36. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors
37. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP
38. Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro
39. Evaluation of the pharmacokinetic interactions of VX-710 with doxorubicin and paclitaxel in beagle dogs
40. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMRP, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats
41. Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles
42. The role of mdr2 P-glycoprotein in biliary lipid secretion: Cross-talk between cancer research and biliary physiology
43. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats
44. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP
45. Very low doses of warfarin can prevent thrombosis in central venous catheters: A randomized prospective trial
46. Phase I/II study with the MDR inhibitor INCELTM (biricodar, VX-710) + doxorubicin in anthracycline resistant advanced soft tissue sarcoma
47. A Phase II study of the safety pharmacokinetics and efficacy of Incel (biricodar, VX-710) in combination with mitoxantrone (M) and prednisone (P) in hormone refractory prostate cancer (HRPC)
48. Clinical pharmacokinetics of doxorubicin
49. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics: A cross-over study
50. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans
51. Investigations on the dose-dependent pharmacokinetics of adriamycin and its metabolites
52. 99-Tcm-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: In vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant
53. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients
54. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer
55. Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression
56. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients
57. m-sestamibi uptake in lung cancer: Relationship with clinical response to chemotherapy
58. Technetium-99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma
59. Technetium-99m-MIBI uptake in small cell lung cancer
60. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi